A Phase I/II Study of Sorafenib and Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer.

Trial Profile

A Phase I/II Study of Sorafenib and Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 15 Apr 2010 Primary outcome amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top